March-in rights are a special tool the government can use to make sure inventions funded by public money benefit the public. Simply put, if a company gets a patent on an invention, but isn’t making it available in a way that helps people, the government can step in. This means the government can allow others to use the invention without the patent holder's permission to protect public interests.
Sounds a bit complicated? Let’s break it down. March-in rights come from the Bayh-Dole Act, a law that lets companies own inventions developed with government funding. The catch is, these companies have to use those inventions properly — to actually improve people’s lives. If they don’t, or if the product isn’t available where it’s needed, march-in rights allow the government to ‘walk in’ and open up use to others.
Here’s the thing: march-in rights aren’t commonly used. Governments are cautious because taking someone else’s patent use rights is serious. Examples of when march-in rights might apply include if the patent holder isn’t making the product accessible or affordable, or if the invention is needed to address a public health emergency. For instance, if a life-saving drug funded by taxpayers isn’t reaching those who need it, the government can step in.
It’s good to remember that march-in rights are there to protect the public, not punish companies. The goal is to balance patent protection with wider access. If companies keep inventions locked away and don’t share the benefits, march-in rights help keep things fair.
March-in rights matter, especially when it comes to medicines, technology, or inventions paid for by taxpayer money. They can affect drug prices, access to new tech, and innovation overall. If you’re curious about how public funding shapes what products come to market, march-in rights are a key piece of the puzzle.
So next time you hear about government-funded research or patents, remember march-in rights — a little-known but powerful way the public can make sure their investment counts. Whether it’s healthcare, energy, or tech, this rule helps keep inventions working for everyone, not just a few.
The Biden administration's proposal to strengthen 'march-in rights' allows the federal government to intervene in licensing research funded by taxpayer money, aiming to lower prescription drug prices and boost competition. Critics argue this could harm innovation and the economy in states like Georgia.
Julian Parsons | Jul, 27 2024 Read More